arrow
K

Krishna Chatterjee

University of Cambridge
H指数:82
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study

三碘甲状腺醋酸(Triac)在甲状腺激素β抵抗(RTHβ)患者中疗效的分子机制:一项多中心、国际性、回顾性队列研究

2026-10-140
OAAI
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine

I期、无针头、剂量递增临床试验:pEVAC-PS,一种候选泛Sarbecovirus疫苗

2026-05-180
OAAI
Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity

甲状腺自身免疫中免疫检查点突变的抗体制备性选择

Nature
IF48.5
2026-04-140
OA
Extreme resistance to thyroid hormone caused by a novel mosaic thyroid hormone receptor beta mutation

van Geest, F.S.; Liao, W.; Voorhoeve, P.G.; Leen, W.G.; Zwaveling-Soonawala, N.; Chatterjee, V.K.; Van den Berg, S.A.A.; Verburg, F.A.; Meima, M.E.; van den Akker, E.L.T.; et al. 由一种新型嵌合甲状腺激素受体β突变引起的甲状腺激素抵抗极端抗性。Eur. Thyroid. J. 2025, 14, e250092. [Google Scholar] [CrossRef] [PubMed]

2025-12-010
PRE
Reply to the letter by Dr Karlsson 'Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan-Herndon-Dudley syndrome with tiratricol?'

回复卡尔森博士的信件:《欧洲甲状腺协会2024年指南将三碘甲状腺原氨酸用于治疗艾伦-赫恩登-达德利综合征的依据?》

2025-10-010
PRE
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Selenoprotein deficiency disorder predisposes to aortic aneurysm formation

硒蛋白缺乏症易导致主动脉瘤形成

2023-12-024
OAAI
Structure-Guided Approach to Relieving Transcriptional Repression in Resistance to Thyroid Hormone α

结构引导的方法来缓解对甲状腺激素 α 的抵抗中的转录抑制

2023-02-275
OAAI
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

BNT162b2和mRNA-1273新型冠状病毒肺炎疫苗在两剂ChAdOx1 nCoV-19或BNT162b2和第三剂BNT162b2 (cov-boost) 后作为第四剂加强剂的安全性,免疫原性和反应原性: 多中心,盲法,2期随机试验

2022-08-01114
OAAI
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

在英国,在两剂ChAdOx1 nCov-19或BNT162b2之后,作为第三剂加强剂给予七种新型冠状病毒肺炎疫苗后的免疫原性持久性: cov-boost试验的三个月分析

2022-06-0147
OAAI
Clonal dynamics of haematopoiesis across the human lifespan

人类一生中造血的克隆动力学

Nature
IF48.5
2022-06-010
OAAI
Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study
2021-10-2226
OA
Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome
2021-10-221
OA